Abstract
This is the first of three chapters that discusses the role and interpretation of subgroup analyses in clinical trials. Subgroup analysis in a clinical trial is the evaluation of the effect of the randomly allocated intervention within only a fraction of the patients in the entire research cohort. This chapter provides some general background on the issue of subgroup evaluation, and discusses some of the interpretative difficulties that occur during the assessment of the effect of therapy within subgroups.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Pfeffer, M.A., Braunwald, E., Moyé, L.A. et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-results of the Survival and Ventricular Enlargement Trial. New England Journal of Medicine 327:669–677.
Sacks F.M. Pfeffer M.A., Moyé, L.A. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 335:1001–1009.
The SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug therapy in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). Journal of the American Medical Association 265:3255–3264
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with CAD and a broad range of initial cholesterol levels. New England Journal of Medicine 339:1349–1357.
Moyé, L.A., Pfeffer, M.A., Wun, C.C., et. al (1994). Uniformity of captopril benefit in the post infarction population: Subgroup analysis in SAVE. European Heart Journal. 15: Supplement B:2–8.
Lewis, S.J., Moyé, L.A., Sacks, F.M., et. al (1998). Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Annals of Internal Medicine 129:681–689.
Lewis, S.J., Sacks, F.M., Mitchell, J.S., et. al (1998). Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. Journal of the American College of Cardiology 32:140–146.
Peto, R., Collins, R., Gray, R. (1995). Large-cale randomized evidence: Large, simple trials and overviews of trials. Journal of Clinical Epidemiology 48:23–40.
MRFIT Investigators. (1982). Multiple risk factor intervention trial Journal of the American Medical Association 248:1465–77.
ISIS-1 Collaborative Group (1986) Randomized trial of intravenous atenolol among 16027 cases of suspected actue myocardial infarction-ISIS-1. Lancet ii;57–66.
Lee, K.L., McNeer, F., Starmer, C.F., Harris, P.J., Rosari, R.A. (1980). Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation 61:508–515.
Assmann, S., Pocock, S., Enos, L., Kasten, L. (2000), Subgroup analysis and other (mis)uses) of baseline data in clinical trials. Lancet 355:1064–69
Bulpitt, C. (1988). Subgroup Analysis. Lancet: 31–34.
Packer, M., O’Connor, C.M., Ghali, J.K., et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group. (1996). Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New England Journal of Medicine 335:1107–14.
Packer, M. Presentation of the results of the Prospective Randomized Amlodipine Survival Evaluation-2 Trial (PRAISE-2) at the American College of Cardiology Scientific Sessions, Anaheim, CA, March 15, 2000.
Exner, D.V., Dreis, D.L., Domanski, M.J., Cohn, J.N. (2001), Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared to white patients with left ventricular dysfunction. New England Journal of Medicine 334:1351–7
Yancy, C.W., Fowler, M.B., Colucci, W.S., Gilber, E.M., Brsitow, M.R., Cohn, J.N., Luka, M.A., Young, S.T., Packer, M. for the US Carvedilol Heart Failure Study Group. 2001. Race and response to adrenergic blockade with carvedilol in patients with chronic heart failure. New England Journal of Medicine 334:1358–65.
Stolberg S.G. Should a pill be colorblind? New York Times. Week in Review. May 13, 2001.p 1.
Moyé, L. (2000) Statistical Reasoning in Medicine: The Intuitive P-Value Primer. New York. Springer.
Yusuf, S., Wittes, J., Probstfield J, Tyroler H.A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. Journal of the American Medical Association 266:93–8.
Pedersen, T.R., Olsson, A.G., Faergeman, O., Kjekshus, J., Wedel, H., Berg, K., Wilhelmensen, L., Haghfelt, T., Thorgeirsson, G., Pyòrälä, K., Miettinen, T., Christophersen. B.G., Tobert, J.A., Musliner, T.A., Cook, T.J. for the Scandinavian Simvastatin Survival Study Group. (1998). Lipoprotein changes and reduction in the incidence of major CAD events in the scandinavian simvastatin survival study (4S). Circulation 97:1453–1460.
West of Scotland Coronary Prevention Study Group. (1996). Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440–1445.
Sacks, F.M., Moyé, L.A., Davis, B.R., Cole, T.B., Rouleau, J.L., Nash, D. Pfeffer, M.A., Braunwald, E. (1998). Relationship between plama LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 97:1446–1452.
Peduzzi, P., Wittes, J., Deter, K., Holford, T. Analysis as-randomized and the problem of non-adherence; an example from the veterans affairs randomized trial of coronary artery bypass surgery. (1993). Statistics in Medicine 12:1185–1195.
Moyé, L.A. for the SAVE Cooperative Group. (1991). Rationale and design of a trial to assess patient survival and ventricular enlargement after myocardial infarction. American Journal of Cardiology 68:70D–79D.
Pfeffer, M.A., Braunwald, E., Moyé, L.A. et al. (1992) Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-results of the Survival and Ventricular Enlargement Trial. New England Journal of Medicine 327:669–677.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998). Prevention of cardiovascular events and death with pravastatin in patients with CAD and a broad range of initial cholesterol levels. New England Journal of Medicine 339:1349–1357.
Rights and permissions
Copyright information
© 2003 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
(2003). Introduction to Subgroup Analyses. In: Multiple Analyses in Clinical Trials. Statistics for Biology and Health. Springer, New York, NY. https://doi.org/10.1007/0-387-21813-0_10
Download citation
DOI: https://doi.org/10.1007/0-387-21813-0_10
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-00727-4
Online ISBN: 978-0-387-21813-7
eBook Packages: Springer Book Archive